New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
- 61% increase in preventative drug prescriptions among high-risk patients
- Improved specialist referrals leading to reduced cost of care and improved patient outcomes
- FDA issued a de Novo Marketing Authorization for the KidneyIntelX.dkd version of the test
- None.
Insights
The deployment of KidneyIntelX, an in vitro prognostic tool, within a major U.S. health system has shown promising Real World Evidence (RWE) in managing chronic kidney disease (CKD) and Type 2 diabetes among patients. The integration of this tool into electronic health records has led to a tailored increase in preventative drug prescriptions and specialist referrals, particularly for those in the high-risk category. This stratified approach is critical, as it facilitates the early identification and management of patients most likely to benefit from intensive care, potentially reducing the long-term burden on healthcare systems.
From a medical research perspective, the improvement in clinical outcomes, such as the eGFR slope and A1C levels, indicates that KidneyIntelX may play a significant role in slowing disease progression. This is particularly relevant given the demographic characteristics of the study population, which include high-risk factors such as advanced age, high BMI and prevalence of hypertension. The use of such diagnostic tools aligns with the precision medicine approach, which aims to tailor healthcare, based on individual variability in genes, environment and lifestyle for each person.
The economic implications of utilizing KidneyIntelX are substantial, considering the potential for reducing the overall cost of care for CKD and Type 2 diabetes. A 61% increase in preventative drug prescriptions and improved specialist referrals suggest that early intervention can mitigate the progression to more severe stages of disease, which are more costly to treat. By improving disease management and patient outcomes, there can be a significant reduction in hospital admissions, dialysis requirements and other expensive interventions.
The study's findings also underscore the value of investing in predictive health technologies. The broad insurance payment coverage, including Medicare and Medicaid, indicates a recognition of the cost-saving potential of such tools. Moreover, the FDA's de Novo Marketing Authorization for KidneyIntelX.dkd version of the test reinforces its clinical and economic value. The addressable market of approximately 14 million patients with adult diabetes and kidney disease represents a substantial opportunity for healthcare cost optimization.
Renalytix's KidneyIntelX presents a significant advancement in the management of CKD and Type 2 diabetes, which could impact the company's market positioning and stock performance. The RWE demonstrating improved patient outcomes and potential cost savings is likely to resonate with healthcare providers and insurers, potentially increasing the adoption rate of the KidneyIntelX system. The positive results and FDA authorization could also enhance investor confidence, potentially leading to an uptick in Renalytix's stock value.
Additionally, the emphasis on a diverse cohort, including 27% black patients, addresses health disparities and may increase the test's market penetration in underserved communities. The healthcare sector's increasing focus on personalized medicine could further drive demand for predictive diagnostic tools like KidneyIntelX, positioning Renalytix favorably within this growing niche market.
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
Results demonstrated a
LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including
Improved kidney health was evidenced by reduction in the rate of kidney function decline (eGFR slope) and diabetes control was evidenced by improved A1C levels. KidneyIntelX testing achieved scale through electronic health record integration, deploying directly to large treating groups of primary care physicians. These improvements, coupled with increase in percentage of KidneyIntelX high-risk patients achieving blood pressure control, have been shown to be associated with improvements in cardiovascular health and outcomes in CKD.
KidneyIntelX has received broad insurance payment coverage including through Medicare, Medicaid, and Blue Cross Blue Shield programs. The Food and Drug Administration (FDA) issued a de Novo Marketing Authorization of the kidneyIntelX.dkd version of the test in June 2023 with an indicated use addressable market of approximately 14 million patients with adult diabetes and kidney disease.
“The demonstrated benefits of KidneyIntelX early risk assessment at one year are significant and go to the core of chronic disease preventative medicine. This real-world data highlights the critical importance of early preventative care and the ability to better control cost and outcomes through efficient electronic deployment of KidneyIntelX bioprognosis,” said Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix. “We look forward to continuing published data releases in coming months in order to support our belief that KidneyIntelX provides actionable information leading to preventative care and improving healthcare outcomes.”
“This published real world evidence puts KidneyIntelX at the intersection of multiple established diabetes, kidney and cardiovascular care guidelines. This data is compelling and shows the importance of adopting KidneyIntelX across primary care networks to help control these unsustainable chronic diseases that unnecessarily effect millions of patients,” said James McCullough CEO of Renalytix.
The study population includes representation of a number of high-risk factors for disease progression including (a) patient median baseline age of 68 years (b)
The RWE study results demonstrated that patients with Type 2 Diabetes and Stage 1-3 CKD and a high-risk KidneyIntelX score received higher frequency of clinical management visits, improved utilization of guideline-recommended medications, and appropriate specialist referral or consultation for disease management compared to those who were identified as low or intermediate risk patients.
For further information, please contact:
| Renalytix plc | www.renalytix.com | |
| James McCullough, CEO | Via Walbrook PR | |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | ||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
| Gary Clarence / Shalin Bhamra | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 | |
| CapComm Partners | ||
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | |
About Chronic Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that
About Type 2 Diabetes
More than 37 million Americans have diabetes (about 1 in 10), and approximately 90
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
Sources
1 https://www.theisn.org/blog/2020/11/27/more-than-850-million-worldwide-have-some-form-of-kidney-disease-help-raise-awareness/
2 https://www.cdc.gov/diabetes/basics/type2.html
3 https://www.cdc.gov/diabetes/data/statistics-report/index.html
4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297507/
Forward Looking Statements
Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the commercial prospects of KidneyIntelX and kidneyintelX.dkd, including whether KidneyIntelX and kidneyintelX.dkd will be successfully adopted by physicians, inform clinical guidelines, lead to clinical actions that improve patient outcomes, achieve expanded insurance coverage and be successfully distributed and marketed, the potential for KidneyIntelX and kidneyintelX.dkd to be expanded and approved for additional indications and in additional jurisdictions, our expectations regarding the impact and benefits of the CMS action on the value or pricing of KidneyIntelX, our expectations with respect to reimbursement decisions, our intellectual property position, our competitive position and the ability of KidneyIntelX and kidneyintelX.dkd to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX and kidneyintelX.dkd are based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including our most recent Quarterly Report on Form 10-Q and the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on September 28, 2023, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
What is the significance of the real-world evidence for KidneyIntelX?
How many patients were included in the study?
What is the addressable market for the KidneyIntelX.dkd version of the test?
What is the significance of the FDA's de Novo Marketing Authorization for KidneyIntelX.dkd?
